Long COVID clinical trial begins in United States.

The research company Resolve Therapeutics is conducting the clinical trial Phase 2 Study of RSLV-132 in Subjects With Long COVID.

The purpose of this study is to assess the efficacy, safety and pharmacokinetics of RSLV-132 in subjects with long Corona Virus (COVID) syndome. It is planned to include 90 participants.

Actual study start date is June 25, 2021. The researchers expect to complete the study by January 31, 2022.

One primary outcome measure is Percentage of subjects with FACIT score improvement, Functional Assessment of Chronic Illness Therapy (FACIT) improvement of at least 6 points from Baseline at the end of treatment.

The further details can be found here: https://ichgcp.net/clinical-trials-registry/NCT04944121.